PlateletDiagnostics, LLC (PlateletDx.com) today announced the development of a first-in-class platelet function assay that measures phosphorylation of the abundant platelet protein, dynamin-related ...

BACKGROUND: Despite antiplatelet therapy, some patients remain at high ischemic risk because of drug nonresponsiveness or high residual platelet reactivity). We aimed to target an orphan platelet GPCR ...

Results of the TRANSLATE-POPS Trial Presented at TCT 2013 SAN FRANCISCO, CA. – According to a new study of heart attack patients treated with percutaneous coronary intervention (PCI), free access to ...

Please provide your email address to receive an email when new articles are posted on . An injection of platelet-rich plasma and gonadotropins near the ovarian follicles may help restore ovarian ...

WASHINGTON, DC—Additional evidence, this time from a phase IIb trial in healthy people ages 50 to 80, supports that bentracimab (PhaseBio) provides a near-immediate reversal of ticagrelor’s ...

Managing drug dosage is critical to the overall success of pharmaceutical intervention, not only in the clinic but also in clinical trials. Inadequate dose management of certain drugs can have fatal ...

Ado-trastuzumab emtansine (T-DM1) treatment results in grade 3-4 thrombocytopenia in 8%-13% of patients. Prior in vitro studies reported T-DM1 inhibition of megakaryocyte maturation as the cause of ...

The coronavirus disease-19 (COVID-19) pandemic that emerged in Wuhan, China, in late December 2019 spread rapidly throughout the world and has caused over 6.5 million deaths. The disease is caused by ...

Use of platelet function testing during dual antiplatelet therapy, including a P2Y12 antagonist, in acute coronary syndromes does not improve clinical outcomes. Researchers at King's College London ...

Outcomes With Local Therapy and Tyrosine Kinase Inhibition in Patients With ALK/ROS1/RET-Rearranged Lung Cancers Ado-trastuzumab emtansine (T-DM1) treatment results in grade 3-4 thrombocytopenia in 8% ...